(Q41738413)

8 October 2017

RNA-binding residues in the N-terminus of APOBEC3G influence its DNA sequence specificity and retrovirus restriction efficiency (English)

1 reference

8 October 2017

Kasandra Bélanger

1

1 reference

PubMed ID

25974865

8 October 2017

Marc-André Langlois

series ordinal

2

1 reference

PubMed ID

25974865

8 October 2017

language of work or name

English

0 references

publication date

15 May 2015

1 reference

8 October 2017

1 reference

8 October 2017

483

1 reference

8 October 2017

141-148

1 reference

Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Characterization of APOBEC3G binding to 7SL RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Deamination intensity profiling of human APOBEC3 protein activity along the near full-length genomes of HIV-1 and MoMLV by HyperHRM analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Antiviral potency of APOBEC proteins does not correlate with cytidine deamination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

APOBEC3G inhibits elongation of HIV-1 reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Crystal Structure of the DNA Cytosine Deaminase APOBEC3F: The Catalytically Active and HIV-1 Vif-Binding Domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Determinants of sequence-specificity within human AID and APOBEC3G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Folding of the multidomain human immunodeficiency virus type-I integrase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

DNA deamination mediates innate immunity to retroviral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

APOBECs and virus restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

The APOBEC3C crystal structure and the interface for HIV-1 Vif binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Guidelines for naming nonprimate APOBEC3 genes and proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

A DNA sequence recognition loop on APOBEC3A controls substrate specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Crystal structure of DNA cytidine deaminase ABOBEC3G catalytic deamination domain suggests a binding mode of full-length enzyme to single-stranded DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Complementary function of the two catalytic domains of APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Immunity through DNA deamination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.019

10.1016/J.VIROL.2015.04.019

7 January 2021

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

25974865